

NEUROLOGY ALERT®

A monthly survey of developments in neurologic medicine

CUMULATIVE INDEX

Volume 25, Numbers 1-12, Pages 1-96

Volume 26, Numbers 1-4, Pages 1-32

September 2006—December 2007

Please note, Volume listed first, then issue number, then page number

A

ACE inhibitors, statins, stroke prevention, 25:2:9
acute disseminated encephalomyelitis, multiple sclerosis, 26:4:28
acute optic neuritis, visual outcome, 26:3:22
acute stroke
 Cheynes-Stokes respiration, 25:8:62
 statin withdrawal, 26:2:9
age, teens, polyneuropathy, 25:1:6
alpha-synuclein promoter variability, Parkinson's disease, 25:2:14
Alzheimer's dementia, biomarkers for, 25:12:95
Alzheimer's disease
 antipsychotics for, 25:5:33
 gingko biloba and donepezil, 25:2:12
 PET imaging, 25:6:43
amnesia, transient global, mechanism of, 25:5:39
amyotrophic lateral sclerosis
 prediction of, 25:7:51, 26:1:2
 or primary lateral sclerosis, 25:8:58
aneurismal subarachnoid hemorrhage, outcome, 26:1:3
anticoagulation-associated intracerebral hemorrhage, 25:8:63
antiepileptic drugs, newer versus older, 25:9:66
antipsychotics, Alzheimer's disease, 25:5:33
atrial fibrillation
 in elderly, warfarin benefit, 26:3:17
 paroxysmal, stroke and, 26:1:7
aura, migraine, cardiovascular risk, 25:1:4

B

Bell's palsy, 26:4:25

bilateral vestibulopathy, common cause of, 25:12:89
biomarkers for Alzheimer's dementia, 25:12:95
brain stimulation, deep, for Parkinson's disease, 25:3:17

C

cabergoline, cardiac valve disorders, 25:6:46
camptocormia, Parkinson's disease and, 25:4:31
cancer patients, status epilepticus, 25:7:49
cardiac surgery, cerebrovascular disease, 25:2:15
cardiac valve disease, Parkinson's disease, 25:6:46
cardiovascular risk, migraine with aura and, 25:1:4
carotid artery stenosis, endarterectomy or stenting, 25:4:25
celiac disease
 dementia in, 25:4:30
 myopathy, 25:10:76
cerebral amyloid angiopathy, diagnosis of, 26:4:29
cerebrovascular disease, cardiac surgery, 25:2:15
Cheynes-Stokes respiration, acute stroke, 25:8:62
childhood, convulsive status epilepticus, epidemiologic findings in, 25:1:3
chronic pain, sleep deprivation and, 25:11:87
cluster headache, 25:2:12
 occipital nerve stimulation, 25:9:71
cognitive impairment, hemodialysis, 25:1:5
convulsive status epilepticus, epidemiologic findings in childhood, 25:1:3

coronary artery bypass graft, cognitive impairment, 26:2:13
Creutzfeldt-Jakob disease, diagnosis of, 25:3:18
CT or MRI imaging, acute stroke, 25:10:73
cyclophosphamide, multiple sclerosis, 25:4:27

D

deep-brain stimulation, dystonia, 25:5:38, 26:4:31
dementia
 Alzheimer's, biomarkers for, 25:12:95
 celiac disease and, 25:4:30
 hemodialysis, 25:1:5
 Parkinson's disease, versus Lewy bodies, 26:2:10
 prediction and diagnosis in HIV, 25:10:75
 telomeres, and mortality, 25:1:1
disc
 herniated lumbar, therapies for, 25:6:41
 transplantation, intervertebral, 25:11:83
disease (*See specific disease listings*)
donepezil, gingko biloba, Alzheimer's disease, 25:2:12
dopamine agonist
 cardiac valve disease, 25:6:46
 Parkinson's disease, 25:2:13
dopaminergic hypoactivity, restless legs syndrome, 25:1:7
driving, Parkinson's disease, 25:6:43, 26:3:20
dystonia
 deep-brain stimulation for, 25:5:38, 26:4:31
 long-distance runners, 25:7:53
 severe tongue protrusion, 25:3:23

E
 EEG monitoring, intracerebral hemorrhage, 26:3:21
 electrodiagnostic studies, sacral plexopathy, 25:12:94
 encephalitis, limbic, antibodies and, 25:9:69
 endarterectomy, stenting, carotid artery stenosis, 25:4:25
 eosinophilic neuropathy, skin and, 26:1:1
 epilepsy
 frontal lobe, surgery for, 25:8:60
 newer versus older drugs for, 25:9:66
 seizure, hormone replacement therapy, 25:4:26
 sensory-motor cortex surgery, 25:5:36
 temporal lobe, hippocampal sclerosis, 25:8:59
 epileptiform discharges, periodic lateralized, cortical and subcortical, 26:2:14
 essential tremor,
 incident dementia, 26:4:30
 pathology of, 25:3:22

F
 fibrates, myopathies and, 25:2:11
 fingolimod, multiple sclerosis, 25:3:19
 frontal lobe epilepsy, surgery for, 25:8:60

G
 genetic risk, lipid-lowering drugs, 25:2:11
 ginkgo biloba, donepezil, Alzheimer's disease, 25:2:12
 gliomas
 malignant, 25:8:57
 treatment of high-grade, 25:10:77
 Guillain-Barré syndrome, predicting respiratory failure in, 26:3:19

H
 headache
 during pregnancy, neuroimaging in, 26:1:6
 cluster, 25:2:12
 occipital nerve stimulation, 25:9:71
 sentinel, subarachnoid hemorrhage rebleeding, 25:5:37
 sexual activity, prognosis and treatment, 26:3:18
 hemianopic alexia, optokinetic therapy for, 25:11:86
 hemodialysis, dementia, 25:1:5
 hemorrhage, intracerebral
 anticoagulation-associated, 25:8:63
 EEG monitoring, 26:3:21
 hemorrhage, subarachnoid, sentinel headache and, 25:5:37
 herniated lumbar discs, therapies for, 25:6:41
 hippocampal sclerosis, temporal lobe epilepsy, 25:8:59
 HIV, dementia prediction and diagnosis, 25:10:75
 hormone replacement therapy, seizure, 25:4:26
 hypotension, spontaneous intracranial, 25:9:65

I
 idiopathic peroneal neuropathy, entrapment, 26:2:12
 immunosuppressive, combined, long-term, for myasthenia gravis, 25:3:21
 impulse control disorders, Parkinson's disease, 25:2:13
 infant, preterm, neonatal MRI, 25:7:50
 intervertebral disc transplantation, 25:11:83
 intracerebral hemorrhage
 anticoagulation-associated, 25:8:63
 EEG monitoring, 26:3:21
 intracranial arterial stenosis, non-invasive testing for, 25:12:92
 intracranial atherosclerotic disease, stenting for, 25:10:79
 intravenous immunoglobulin, myasthenia gravis and Miller Fisher syndrome, 25:9:68
 ischemic attack, transient, management of, 25:4:29
 ischemic stroke risk, lipoprotein(a), 25:7:54

K
 ketogenic diet, safety of long-term use, 25:6:47

L
 levodopa, Parkinson's disease, 26:1:5
 Lewy bodies, dementia with, versus Parkinson's disease with dementia, 26:2:10
 limbic encephalitis, antibodies and, 25:9:69
 lipid-lowering drugs, genetic risk, 25:2:11
 lipoprotein(a), ischemic stroke risk, 25:7:54
 lumbar discs, herniated, therapies for, 25:6:41
 lumbar spinal surgery versus conservative treatment, 25:11:81
 lupus, nervous system, 26:4:26-27

M
 malignant gliomas, 25:8:57

migraine
 aura, and cardiovascular risk, 25:1:4
 female smoking, stroke risk, 26:2:15
 men, stroke risk, 25:10:78
 Miller Fisher syndrome, myasthenia gravis, intravenous immunoglobulin, 25:9:68
 mortality, telomeres, and dementia, 25:1:1
 MRI
 neonatal, preterm infants, 25:7:50
 or CT imaging, acute stroke, 25:10:73
 multiple sclerosis
 acute disseminated encephalomyelitis, 26:4:28-29
 childhood onset, 25:12:91
 cyclophosphamide, 25:4:27
 fingolimod for, 25:3:19
 immune therapy, genetic risk factors, 26:4:30
 low vitamin D, 25:7:52
 pain prevalence, 25:6:45
 myasthenia gravis
 combined immunosuppressive therapy, long-term, 25:3:21
 Miller Fisher syndrome, intravenous immunoglobulin, 25:9:68
 myocardial infarction risk, migraine in men, 25:10:78
 myopathies, lipid-lowering drugs and, 25:2:11
 myopathy, celiac disease, 25:10:76

N
 neonatal MRI, preterm infants, 25:7:50
 neuritis, optic, acute, visual outcome, 26:3:22
 neuropathy
 eosinophilic, skin and, 26:1:1
 idiopathic peroneal, entrapment, 26:2:12
 peripheral, Sjogren syndrome, 25:6:44
 neurosarcoidosis, treatment for, 25:11:85
 neurotransmission, dopamine, restless legs syndrome and, 25:1:7

O
 occipital nerve stimulation, cluster headache, 25:9:71
 optic neuritis, acute, visual outcome, 26:3:22
 optokinetic therapy, hemianopic alexia, 25:11:86

P
 pain
 chronic, sleep deprivation and, 25:11:87
 prevalence, multiple sclerosis, 25:6:45

- Parkinson's disease
 alpha-synuclein promoter variability, 25:2:14
 camptocormia for, 25:4:31
 cardiac valve disease, 25:6:46
 deep-brain stimulation for, 25:3:17
 dopamine agonist medications, 25:2:13
 driving, 26:3:20, 25:6:43
 gene therapy for, 25:12:93
 impulse control disorders, 25:2:13
 levodopa, 26:1:5
 REM sleep and normalization of movement, 25:9:70
 rotigotine patch for, 25:11:84
 with dementia, dementia with Lewy bodies, 26:2:10
- paroxysmal atrial fibrillation, stroke and, 26:1:7
- pergolide, cardiac valve disorders, 25:6:46
- periodic lateralized epileptiform discharges, cortical and subcortical, 26:2:14
- peripheral neuropathy, Sjogren syndrome, 25:6:44
- peroneal entrapment neuropathy, 26:2:12
- PET imaging, Alzheimer's disease, 25:6:43
- polyneuropathy, teenagers, 25:1:6
- pregnancy, headache, neuroimaging in, 26:1:6
- preterm infants, neonatal MRI in, 25:7:50
- primary lateral sclerosis, or amyotrophic lateral sclerosis, 25:8:58
- pulsatile tinnitus, 25:3:20
- R**
- REM sleep, normalization of movement and Parkinson's disease, 25:9:70
- respiratory failure, prediction in Guillain-Barré syndrome, 26:3:19
- restless legs syndrome, dopaminergic hypoactivity, 25:1:7
- rotigotine patch, Parkinson's disease, 25:11:84
- S**
- sacral plexopathy, electrodiagnostic studies, 25:12:94
- sclerosis
 amyotrophic lateral, prediction of, 25:7:51, 26:1:2
 hippocampal, temporal lobe epilepsy, 25:8:59
 multiple
 childhood onset of, 25:12:91
 cyclophosphamide, 25:4:27
 fingolimod for, 25:3:19
 low vitamin D, 25:7:52
 pain prevalence, 25:6:45
 primary lateral or amyotrophic lateral, 25:8:58
- seizure
 hormone replacement therapy, 25:4:26
 ketogenic diet, long-term, 25:6:47
 reduction, ketogenic diet and long-term use, 25:6:47
- sensory-motor cortex surgery, epilepsy, 25:5:36
- severe tongue protrusion dystonia, 25:3:23
- sexual activity and headache, prognosis and treatment, 26:3:18
- Sjogren syndrome, peripheral neuropathy, 25:6:44
- sleep deprivation, chronic pain and, 25:11:87
- small-cell lung cancer, brain radiotherapy for, 26:4:27-28
- smoking, female, migraine, stroke risk and, 26:2:15
- spinal surgery, lumbar, versus conservative treatment, 25:11:81
- spontaneous intracranial hypotension, 25:9:65
- starvation, neurological consequences of, 25:5:35
- statins
 ACE inhibitors, stroke prevention, 25:2:9
 myopathies and, 25:2:11
 withdrawal, acute stroke, 26:2:9
- status epilepticus
 cancer patients, 25:7:49
 convulsive, and epidemiologic findings in childhood, 25:1:3
- stenosis, intracranial arterial, non-invasive testing for, 25:12:92
- stenting
 endarterectomy, carotid artery stenosis, 25:4:25
 intracranial atherosclerotic disease, 25:10:79
- stimulation
 deep-brain,
 dystonia, 25:5:38
 for Parkinson's disease, 25:3:17
 occipital nerve, cluster headache, 25:9:71
- stroke
 acute,
 Cheynes-Stokes respiration, 25:8:62
 statin withdrawal, 26:2:9
 female smoking and migraine, 26:2:15
 ischemic risk, lipoprotein(a), 25:7:54
 MRI or CT imaging for, 25:10:73
 prevention
 intracranial stenting, 25:10:79
 statins and ACE inhibitors for, 25:2:9
 risk, migraine in men, 25:10:78
 symptomatic carotid stenosis, 25:4:25
 telemedicine for, 26:2:11
 subarachnoid hemorrhage, aneurismal, outcome, 26:1:3
 subdural hematoma, spontaneous intracranial hypotension, 25:9:65
 subthalamic nucleus, deep brain stimulation, Parkinson's disease, 25:3:17
- T**
- teenagers, polyneuropathy in, 25:1:6
- telemedicine for stroke, 26:2:11
- telomeres, dementia, and mortality, 25:1:1
- temporal lobe epilepsy, hippocampal sclerosis, 25:8:59
- tinnitus, pulsatile, 25:3:20
- tissue plasminogen activator, stroke, telemedicine, 26:2:11
- transient global amnesia, mechanism of, 25:5:39
- transient ischemic attack, management of, 25:4:29
- tremor, essential
 incident dementia, 26:4:30
 pathology of, 25:3:22
- V**
- vestibulopathy, bilateral, common cause of, 25:12:89
- vitamin D, multiple sclerosis, 25:7:52
- W**
- warfarin, atrial fibrillation in elderly, 26:3:17
- Wernicke's encephalopathy, starvation and, 25:5:35

